Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Companyâs core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. Source
No articles found.
Phio Pharmaceuticals is focused on developing the next generation of immuno-oncolo...
Phio Pharmaceuticals is focused on developing t...
Aurinia is a late clinical stage biopharmaceutical company focused on developing a...
Aurinia is a late clinical stage biopharmaceuti...
AzurRx BioPharma is a development stage biopharmaceutical company (NASDAQ: AZRX) f...
AzurRx BioPharma is a development stage biophar...
VistaGen Therapeutics (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company...
VistaGen Therapeutics (NASDAQ: VTGN) is a clini...
Sophiris Bio Inc. is a late-stage biopharmaceutical company developing topsalysin ...
Sophiris Bio Inc. is a late-stage biopharmaceut...
LifeBridge 10000, LLC specializes in extending and improving the quality of life f...
LifeBridge 10000, LLC specializes in extending ...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Join the National Investor Network and get the latest information with your interests in mind.